Vitamin K2 100 mcg by Mason Natural — Ingredients, Evidence & Safety

🟢 100/100

This product looks safe

No ingredients exceed tolerable upper intake levels
50% of ingredients have research evidence

A Label Compliance Grade

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size

100 Servings

Single Vitamin and Mineral Product Type

50% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin K

100 mg (83% DV)

📊 833.3× RDA — above typical dose 📚 273 studies (Tier A: 9, B: 175)

RDA 0.12mg This product: 100mg

Calcium

40 mg (4% DV)

Other Ingredients

Microcrystalline Cellulose Stearic Acid Croscarmellose Sodium Magnesium Stearate Silicon Dioxide

Label Claims — Verification

❓ All Other

❓ Structure/Function

All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Directions: Adults - take one tablet daily, preferably with food, as a dietary supplement.

⚠️ Warnings & Precautions

Warning: If you are pregnant, nursing, taking any medications or planning any medical procedure, consult your physician before use.

Discontinue use and consult your physician if any adverse reactions occur.

Keep out of reach of children.

Tamper-Evident Seal: Do not use product if seal appears tampered.

🧪 Formulation Notes

Guaranteed no added: Sugar, Starch, Yeast, Soy, Corn, Wheat, Dairy, Fish, Tree Nuts, Peanuts, Eggs, Crustacean Shellfish, Fragrance, Artificial Colors, Artificial Flavors, and Preservatives. Sodium free.

Soy free

Additional Information

1768-100

Mason guarantee Laboratory Tested

cGMP Certified Good Manufacturing Practice

Certified

Est. 1967

May Support General Health

Soy free

Store in a dry place under controlled room temperature: 20(0)-25(0)C (68(0)-77(0)F).

Product Details

UPC / SKU 3 11845 17681 3

DSLD Entry Date 2019-06-24

Product Type Single Vitamin and Mineral

Form Tablet or Pill

Brand Mason Natural

DSLD ID 202116

Data Updated 2026-04-11

Research Evidence

332 Research Sources

59 Avg Quality Score

220 Meta Analysis

56 Systematic Review

30 Rct

16 Clinical Trial

3 Guideline

3 Regulatory Source

1 Narrative Review

1 Other

1 Openfda Safety

A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI Cochrane

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI

A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2016

PubMed DOI

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI

A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2025

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation

Meta Analysis The Cochrane database of systematic reviews 2018

PubMed DOI

A Antiplatelet agents and anticoagulants for hypertension

Systematic Review The Cochrane database of systematic reviews 2022

PubMed DOI

A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Meta Analysis The Cochrane database of systematic reviews 2012

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation